SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ — Talphera, Inc. (Nasdaq: TLPH), (“Talphera”), a specialty pharmaceutical firm targeted on the event and commercialization of revolutionary therapies to be used in medically supervised settings, immediately introduced that administration will take part in a hearth chat on the 2024 Maxim Healthcare Digital Summit and will probably be out there for 1×1 conferences with registered buyers. The summit is being held on October 15-17, 2024.
Occasion: 2024 Maxim Healthcare Digital Summit
Date: October 16, 2024
Time: 3:00 PM ET / 12:00 Midday PT
Webcast hyperlink: 2024 Maxim Healthcare Digital Summit
About Talphera, Inc.Talphera, Inc. is a specialty pharmaceutical firm targeted on the event and commercialization of revolutionary therapies to be used in medically supervised settings. Talphera’s lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is presently being studied below an investigational gadget exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has acquired Breakthrough System Designation standing from the U.S. Meals and Drug Administration (FDA).
This launch is meant for buyers solely. For extra details about Talphera, please go to www.talphera.com.